(Washington) American health officials on Friday announced that they are urgently approving a new treatment against the bevtelovimab monoclonal antibody Kovid-19, which is effective against the omicran variant.
Posted yesterday at 5:45 p.m.
This treatment is active, including a sub-variant of Omicron BA.2 specified by the American Medicines Agency (FDA).
Produced by the pharmaceutical group Eli Lily, it is offered to people at risk of developing a severe case of the disease from the age of 12 years.
In clinical trials, side effects may include itching, nausea or vomiting.
In mid-January, the FDA withdrew its emergency authorization of two therapies from monoclonal antibodies and Eli Lily (Bamlanivimab and Etesevimab) from Regeneran (Kasirivimab and Imdevimab) because they were no longer effective against Omicron.
Monoclonal antibodies are synthetic proteins that mimic the immune system’s ability to support the virus.
Usually injected intravenously, they work by attaching themselves to the spike protein on the surface of the virus, which is the key to entering the body.
